0.6952
Cue Biopharma Inc stock is traded at $0.6952, with a volume of 66,632.
It is up +0.46% in the last 24 hours and up +10.05% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.692
Open:
$0.692
24h Volume:
66,632
Relative Volume:
0.42
Market Cap:
$47.74M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.764
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-11.93%
1M Performance:
+10.05%
6M Performance:
-49.99%
1Y Performance:
-29.06%
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CUE
Cue Biopharma Inc
|
0.6952 | 47.74M | 9.53M | -44.61M | -38.32M | -0.91 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-24 | Initiated | Jefferies | Buy |
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Nov-21-22 | Initiated | Piper Sandler | Overweight |
Jan-13-22 | Initiated | H.C. Wainwright | Buy |
Jan-03-22 | Initiated | Craig Hallum | Buy |
Nov-24-20 | Initiated | Berenberg | Buy |
Apr-09-20 | Initiated | Stifel | Buy |
Jan-28-20 | Initiated | BTIG Research | Buy |
Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Millennium Management LLC Reduces Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Bank of America Corp DE Acquires 85,113 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
CueBiopharma (CUE) Appoints Interim CFO as Kerri-Ann Millar Resi - GuruFocus
Cue Biopharma CFO Kerri-Ann Millar to Depart - marketscreener.com
Cue Biopharma CFO Resignation and Board Appointment - TipRanks
Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO - marketscreener.com
Jane Street Group LLC Has $70,000 Stock Holdings in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by Northern Trust Corp - Defense World
Stifel Financial Corp Grows Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Transcript : Cue Biopharma, Inc.Special Call - marketscreener.com
Cue Biopharma Inc Reports Q1 2025 Earnings: EPS of -$0.17 Misses Estimate, Revenue Falls Short at $0.4 Million - GuruFocus
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates - MSN
Cue Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cue Biopharma (CUE) Reports Revenue Miss for Q1 2025 | CUE Stock News - GuruFocus
Cue Biopharma Reports Strategic Collaboration with Boehringer Ingelheim and Financial Results for Q1 2025 - Nasdaq
Cue Biopharma (CUE) Schedules Virtual Investor Event to Showcase Biologics Platform | CUE Stock News - GuruFocus
Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - The Manila Times
Cue Biopharma to Participate in Fireside Chat at the Citizens Li - GuruFocus
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - The Manila Times
Cue Biopharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
LPL Financial LLC Has $47,000 Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
CUECue Biopharma Inc Latest Stock News & Market Updates - Stock Titan
Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia
Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa
Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN
Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus
Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma
Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech
Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard
Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter
Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India
Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia
Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus
Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):